Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience

Background: Immune checkpoint inhibitors (ICIs) have widened the therapeutic scenario of different solid tumors over the last ten years. Gastrointestinal (GI) adverse events (AEs), such as diarrhea and colitis, occur in up to 50% of patients treated with ICIs. Materials and methods: We conducted a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Parente, Paola, Maiorano, Brigida Anna, Ciardiello, Davide, Cocomazzi, Francesco, Carparelli, Sonia, Guerra, Maria, Ingravallo, Giuseppe, Cazzato, Gerardo, Carosi, Illuminato, Maiello, Evaristo, Bossa, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947154/
https://www.ncbi.nlm.nih.gov/pubmed/35328239
http://dx.doi.org/10.3390/diagnostics12030685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947154/
https://www.ncbi.nlm.nih.gov/pubmed/35328239
http://dx.doi.org/10.3390/diagnostics12030685

Ejemplares similares